The Lancet Infectious Diseases· Rosalie W Groenendijk, Zazie Franck, Ranju Baral, Leonardo J Basso, Facundo D Batista, Marc Bonten, Mauricio T Caballero, Andrew Clark, Cheryl Cohen, Matthieu Domenech de Cellès, Ignacio Esteban, Ann R Falsey, Slim Fourati, Barney S Graham, Natasha Halasa, Tina Hartert, Aranka L Kops, Leyla Kragten-Tabatabaie, Lies Kriek, Paolo Manzoni, David J Marchant, Federico Martinon-Torres, Asuncion Mejias, Fabio Midulla, Annettee Nakimuli, M Imran Nisar, Joyce U Nyiro, Pedro A Piedra, Peter C Richmond, Farina L Shaaban, Padmini Srikantiah, Renato T Stein, Afshan B Tahibo, Jonne Terstappen, Mariana Viegas, Carla Vizzotti, Conall H Watson, Liang En Wee, Daniel M Weinberger, Louis J Bont, Natalie I Mazur·· 4 小时前AI 评分42
综述：呼吸道合胞病毒免疫预防在实践中的效果
[Review] Effectiveness of respiratory syncytial virus immunisation in practice
AI 导读
呼吸道合胞病毒（RSV）免疫预防已有多种产品获批，但高成本使其实施仍局限于较高收入地区。获批产品包括孕妇疫苗、婴儿用单克隆抗体，以及老年人和高风险成人疫苗。另有39个候选产品处于临床开发阶段，但一种前景可期的儿童减毒活疫苗候选产品已停止开发。
来源：The Lancet Infectious Diseases · thelancet.com